Joseph S Dolina
Overview
Explore the profile of Joseph S Dolina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dolina J, Lee J, Brightman S, McArdle S, Hall S, Thota R, et al.
J Clin Invest
. 2023 Sep;
133(17).
PMID: 37655661
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition...
2.
Brightman S, Becker A, Thota R, Naradikian M, Chihab L, Soria Zavala K, et al.
Nat Immunol
. 2023 Jul;
24(8):1391.
PMID: 37464051
No abstract available.
3.
Brightman S, Becker A, Thota R, Naradikian M, Chihab L, Soria Zavala K, et al.
Nat Immunol
. 2023 Jul;
24(8):1345-1357.
PMID: 37400675
CD4 T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8 T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8 T...
4.
Dolina J, Lee J, Brightman S, McArdle S, Hall S, Thota R, et al.
bioRxiv
. 2023 May;
PMID: 37205330
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition...
5.
Dolina J, Lee J, Moore E, Hope J, Gracias D, Matsutani T, et al.
Proc Natl Acad Sci U S A
. 2022 Mar;
119(10):e2113329119.
PMID: 35239442
SignificanceThe CD4 T response following acute infection is heterogeneous and deploys two distinct modes of suppression coinciding with initial pathogen exposure and resolution of infection. This bimodal suppression of CD8...
6.
Budimir N, Thomas G, Dolina J, Salek-Ardakani S
Cancer Immunol Res
. 2021 Dec;
10(2):146-153.
PMID: 34937730
Anti-PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized the treatment of many types of cancer over the past decade. The initial therapeutic hypothesis underlying the mechanism of anti-PD-1/PD-L1 ICB was...
7.
Dolina J, Van Braeckel-Budimir N, Thomas G, Salek-Ardakani S
Front Immunol
. 2021 Aug;
12:715234.
PMID: 34354714
A paradigm shift in the understanding of the exhausted CD8 T cell (T) lineage is underway. Originally thought to be a uniform population that progressively loses effector function in response...
8.
Dolina J, Lee J, Griswold R, Labarta-Bajo L, Kannan S, Greenbaum J, et al.
Cell Rep
. 2020 Apr;
31(1):107249.
PMID: 32268093
CD4 T lymphocytes are crucial for controlling a range of innate and adaptive immune effectors. For CD8 cytotoxic T lymphocyte (CTL) responses, CD4 T cells can function as helpers (T)...
9.
Chiodetti A, Sanchez Vallecillo M, Dolina J, Crespo M, Marin C, Schoenberger S, et al.
Front Immunol
. 2018 Oct;
9:2319.
PMID: 30364187
There is a need for new vaccine adjuvant strategies that offer both vigorous antibody and T-cell mediated protection to combat difficult intracellular pathogens and cancer. To this aim, we formulated...
10.
Dolina J, Cechova S, Rudy C, Sung S, Tang W, Lee J, et al.
J Immunol
. 2018 Sep;
201(8):2521.
PMID: 30217828
No abstract available.